Idorsia's P2Y12 receptor antagonist selatogrel has significantly inhibited platelet aggregation in two phase 2 trials. The primary endpoint successes in patients with stable coronary artery disease (CAD) or acute myocardial infarction (AMI) set ...

 

Idorsia's selatogrel hits goals in phase 2 cardiovascular trials and more...

Submit a Press Release to Cafepharma

Idorsia's selatogrel hits goals in phase 2 cardiovascular trials

Idorsia's P2Y12 receptor antagonist selatogrel has significantly inhibited platelet aggregation in two phase 2 trials. The primary endpoint successes in patients with stable coronary artery disease (CAD) or acute myocardial infarction (AMI) set Idorsia up to plan the initiation of a phase 3 study.

      
 
 
 

[video+transcript] Gene-Editing Stocks Took Stutter Steps Forward in 2018

For our listeners, for investors out there, gene editing headlines likely have filled your news feeds over the past year or two, some for good reasons, some for not-so-good reasons. The promise and hype of gene editing, being able to actually go to the underlying cause of disease and correct it before the disease even starts, has been a huge opportunity, obviously a ton of investor enthusiasm.

      
 
 
 

Sanofi Moving 2,700 Staffers From the Boston Suburbs to Cambridge Crossing

Paris-based Sanofi signed the lease on two buildings yet to be built in East Cambridge, Massachusetts. Sanofi is the state’s largest life science employer and plans to shift 2,700 staffers into the two buildings at Cambridge Crossing.

      
 
 
 

Alkermes/Biogen hope for less tummy trouble with new MS pill

Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s older MS drug, Tecfidera.

      
 
 
 

Entrada Therapeutics Nabs $59M for Drugs that Gain “Entry” to Cells

When it comes to getting a drug into a cell, size matters. Small molecules can easily pass through the cellular membrane in a way that larger therapeutic proteins can’t, which makes it difficult to develop a biological drug that can reach its target, says Dipal Doshi, CEO of biotech startup Entrada Therapeutics.

      
 
 
 


 

Contact Us

Submit a Press Release to Cafepharma

Past Issues

Unsubscribe